It seems like the long term sale of CBD oil is likely not going to continue as it has (even though right now, given its high price, it isn’t likely that anyone is taking it at the required levels to be helpful for schizophrenia).
"The FDA’s… answer related to whether cannabidiol (“CBD”), a non-narcotic extract of industrial hemp, can be marketed as a dietary supplement, a position that was unclear following a set of warning letters FDA released in February 2015. FDA’s current response, pasted below, is both unqualified and possibly open to review.
“No. Based on available evidence, FDA has concluded that cannabidiol products are excluded from the dietary supplement definition under section 201(ff)(3)(B)(ii) of the FD&C Act. Under that provision, if a substance (such as cannabidiol) has been authorized for investigation as a new drug (an IND was filed in 2014 relative to a CBD-based epilepsy drug) for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for cannabidiol.”
Source: